Table 3.
IDR-B region specific mabs (% inhibition *) | IDR-A region specific mabs (% inhibition *) | ||||
---|---|---|---|---|---|
Antibodies | mab 15 | mab 18 | mab 64 | mab 2 | mab 47 |
Pre-immune | 4 | 5 | 5 | 6 | 4 |
P12 | 5 | 6 | 11 | 20 | 0 |
P14 | 97 | 93 | 86 | 3 | 1 |
P18 | 6 | 7 | 8 | 17 | 2 |
P43 | 4 | 10 | 10 | 27 | 99 |
P12 + P14 | 100 | 100 | 87 | 48 | 5 |
P18 + P14 | 100 | 100 | 93 | 22 | 8 |
P14 + P43 | 100 | 100 | 95 | 40 | 92 |
P12 + P18 | 10 | 13 | 11 | 45 | 12 |
P12 + P43 | 12 | 24 | 18 | 70 | 95 |
P18 + P43 | 10 | 20 | 15 | 46 | 96 |
P12 + P14 + P18 | 100 | 100 | 92 | 75 | 17 |
P12 + P14 + P43 | 100 | 100 | 93 | 78 | 99 |
P18 + P14 + P43 | 100 | 100 | 98 | 50 | 98 |
P12 + P14 + P18 + P43 | 100 | 100 | 98 | 72 | 99 |
P4 + P30 + P32 | 10 | 14 | 13 | 11 | 7 |
Blood donor serum pool | 0 | 0 | 1 | 2 | 0 |
Graves’ patients’ serum pool (n = 20) | 97 | 96 | 77 | 82 | 14 |
standard deviation for all results in Table 1 were between 4 and 8%.